Preliminary safety and radiation dosimetry results from Phase I clinical trial of Ga-68-NGUL, a novel PSMA targeting agent

JOURNAL OF NUCLEAR MEDICINE(2021)

引用 0|浏览16
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要